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Abstract
Background: Surgical treatment for pulmonary metastases is known to be a safe and potentially curative
procedure for various primary malignancies. However, there are few reports regarding the prognostic role of
surgical treatment for pulmonary metastases from esophageal carcinoma, especially after definitive
chemoradiotherapy (CRT).
Methods: We retrospectively reviewed 5 patients who underwent surgical treatment for pulmonary metastases
from esophageal carcinoma at our institution. The primary treatment for esophageal carcinoma was definitive CRT,
and a complete response (CR) was achieved in all patients.
Results: The surgical procedure for pulmonary metastases was wedge resection, and pathological complete
resection was achieved in all 5 patients. The disease free interval after definitive CRT varied from 7 to 36 months,
with a median of 19 months. There were no perioperative complications, but postoperative respiratory failure
occurred in 1 patient. The postoperative hospital stay varied from 4 to 7 days, with a median of 6 days. Three
patients are now alive with a good performance status (PS) and are disease free. The other 2 patients died of
primary disease. The overall survival after surgical treatment varied from 20 to 90 months, with a median of 29
months.
Conclusions: Surgical treatment should be considered for patients with pulmonary metastases from esophageal
carcinoma who previously received CRT and achieved a CR, because it provides not only a longer survival, but also
a good postoperative PS for some patients.
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Background
Surgical treatment for pulmonary metastases is known
to be a safe and potentially curative procedure for var-
ious epithelial tumors, germ cell tumors, and sarcomas.
For example, in the case of surgical treatment for pul-
monary metastases from colorectal cancer, the reported
overall 5-year survival rate is approximately 40% [1-5].
Even if colorectal metastases extended to both the lungs
and liver, surgical treatment can still provide a survival
benefit for properly selected patients.
On the other hand, there are few reports regarding the
role of surgical treatment for pulmonary metastases
from esophageal carcinoma [6,7]. Esophageal carcinoma
can cause systemic spread at an early stage [8], and eso-
phageal pulmonary metastases are often detected as
multiple lesions, accompanied with other sites of metas-
tasis. Reflecting these lethal propensities of esophageal
carcinoma, surgical treatment for pulmonary metastases
from esophageal carcinoma is rarely performed. This is* Correspondence: y.kozu@scchr.jp
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presumably the main reason why there have so far been
few reports.
Nevertheless, the lungs are one of the most frequent
sites of metastases from esophageal carcinoma, and it is
of paramount importance to conduct further investiga-
tions to identify an effective therapeutic modality for
pulmonary metastases from esophageal carcinoma. In
this article, we report our institutional experience with
surgical treatment for pulmonary metastases from eso-
phageal carcinoma after definitive chemoradiotherapy
(CRT).
Methods
After obtaining institutional review board approval, we
retrospectively reviewed a total of 5 patients who under-
went surgical treatment for pulmonary metastases from
esophageal carcinoma at the Shizuoka Cancer Center,
Shizuoka, Japan, between September 2002 and Decem-
ber 2010. All patients had received definitive CRT for
esophageal carcinoma as the primary treatment, and a
complete response (CR) was achieved. Follow-up radi-
ological examinations were performed using the follow-
ing method unless the patient presented with clinical
symptoms; chest X-rays at every examination in the out-
patient department, and computed tomography (CT)
scans of the chest and abdomen every 3-6 months. The
median follow-up period was 29 months (range, 20-90).
During the follow-up period, newly detected round-
shaped pulmonary lesions on radiological examination
were regarded as metastases from esophageal carcinoma.
The selection criteria for surgical treatment of the pul-
monary metastases from esophageal carcinoma were as
follows; (i) the patient has a performance status (PS) of
0 or 1 based on the ECOG scale and can tolerate sur-
gery, (ii) there is radiological evidence of the resectabil-
ity of all pulmonary metastases, (iii) the primary
esophageal carcinoma is controlled, and (iv) there are
no metastatic lesions other than those in the lungs. All
patients met these criteria when pulmonary metastases
were detected, and therefore underwent surgical treat-
ment. The pre-treatment clinical staging for esophageal
carcinoma was based on the 2009 International Union
Against Cancer TNM classification. The histological
diagnosis of the resected pulmonary specimens was
made by at least 2 experienced pathologists. After con-
firming not only the histological similarity between the
resected pulmonary specimens and the esophageal carci-
noma, but also the unlikelihood of a second primary
lung cancer, they diagnosed the resected pulmonary spe-
cimens to be metastatic. We analyzed the clinicopatho-
logical data of all patients in detail regarding esophageal
carcinoma, pulmonary metastases, surgical procedure,
perioperative complications, postoperative hospital stay,
disease free interval (DFI), and overall survival (OS).
The DFI was calculated as the period from the start of
CRT until initial detection of pulmonary metastases on
the follow-up CT-scan. The OS was calculated as the
period from pulmonary metastasectomy until death or
the date of the last follow-up evaluation.
Results
Our study included 5 males with a median age at surgery
of 68 years (range, 55-74). Esophageal carcinoma was
located in cervical esophagus (Ce) in 3 patients, and in the
upper thoracic esophagus (Ut) in 2 patients. The histologi-
cal type of esophageal carcinoma was squamous cell carci-
noma (SCC) in all patients. The pre-treatment clinical
stage of the esophageal carcinoma was IIIA and IIIC in 1
and 4 patients, respectively. The reason for the choice of
definitive CRT rather than surgery as the primary treat-
ment for esophageal carcinoma was unresectability due to
invasion to the subclavian artery in 1 patient, and refusal of
surgery by 4 patients. CRT consisted of 2 cycles of cisplatin
40 mg/m2 on days 1 and 8 and continuous infusion of 5-
fluorouracil 400 mg/m2 on days 1 to 5 and 8 to 12, with
concurrent irradiation of 60 Gy in 30 fractions. In 1 patient,
nedaplatin was administered instead of cisplatin because of
the patient’s renal function. The DFI varied from 7 to 36
months, with a median of 19 months. Before detection of
the pulmonary metastasis, one patient underwent a total
pharyngolaryngoesophagectomy for local recurrence. Che-
motherapy with docetaxel (DOC) was delivered prior to
pulmonary resection in 1 patient, resulting in progressive
disease (PD). The surgical procedure used for pulmonary
metastases was wedge resection, and pathological complete
resection was achieved in all patients. We omitted hilar
and mediastinal lymph node dissection during surgery,
because there were no enlarged or suspicious lymph nodes
noted on the preoperative radiological examination. All
resected pulmonary specimens were diagnosed as metas-
tases from esophageal carcinoma. The number of pulmon-
ary metastasis was 1 in 3 patients, and 2 in 2 patients.
Except for 1 micrometastasis, the diameter of the pulmon-
ary metastasis varied from 6 to 20 mm, with a median of
12 mm. Respiratory failure occurred postoperatively in 1
patient. The postoperative hospital stay varied from 4 to 7
days, with a median of 6 days. During the follow-up period,
another pulmonary metastasis developed in 1 patient, and
pulmonary resection was performed again. The OS varied
from 20 to 90 months, with a median of 29 months. Three
patients are currently alive without recurrence, and the
other 2 patients died of primary disease. The details of the
patients’ backgrounds are shown in Tables 1 and 2.
Patient descriptions
Patient 1
A 69-year-old male was diagnosed with esophageal SCC
in the Ce. A pre-treatment CT-scan revealed direct
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invasion to the trachea (clinical stage T4bN0M0). He
chose CRT as the primary treatment, and a CR was
achieved. Six months after the start of CRT, a local
recurrence developed, so we performed salvage surgery
via total pharyngolaryngoesophagectomy with recon-
struction by the free jejunum. On a follow-up CT-scan,
a solitary pulmonary metastasis was detected 30 months
after the salvage surgery. Pulmonary wedge resection
was performed, and pathological complete resection was
achieved. The patient’s postoperative hospital stay was 6
days. He has been disease free for 41 months after pul-
monary resection, and was doing well in a check-up per-
formed in the outpatient department of our institution.
Patient 2
A 59-year-old male was diagnosed with esophageal SCC
in the Ce. A pre-treatment CT-scan revealed direct
invasion to the trachea (clinical stage T4bN1M0), and
bilateral recurrent nerve paralysis was also detected by a
laryngeal fiberscope. He chose CRT as the primary
treatment, and a CR was achieved. Twenty months after
the start of CRT, a follow-up CT-scan revealed a left
pneumothorax which had developed secondary to pul-
monary metastasis (Figure 1). The air leak persisted
even after treatment with chest tube drainage. Subse-
quently, pulmonary wedge resection was performed, and
pathological complete resection was achieved. Post-
operatively, respiratory failure caused by bilateral recur-
rent nerve paralysis occurred, requiring re-intubation
and tracheostomy. He recovered well soon after these
procedures. The patient’s postoperative hospital stay was
7 days. Four months later, a local recurrence developed,
and he received a total of 6 cycles of cisplatin and 5-
fluorouracil. The therapeutic effect resulted in PD, with
the appearance of new lung metastasis. He died of dis-
ease 29 months after pulmonary resection.
Table 1 Clinicopathological features of the 5 patients with esophageal carcinoma
Patient
1 2 3 4 5
Age 69 59 68 74 55
Gender M M M M M
Location Ce Ce Ce Ut Ut
Clinical stage (TNM) IIIC (T4bN0M0) IIIC (T4bN1M0) IIIC (T4bN1M0) IIIA (T3N1M0) IIIC (T4bN1M0)
Histology SCC SCC SCC SCC SCC
CRT regimen FP + RT FP + RT FP + RT NF + RT FP + RT
Therapeutic effect of CRT CR CR CR CR CR
First recurrence site Locala Lung Lung Lung Lung
M, male; Ce, cervical esophagus; Ut, upper thoracic esophagus; SCC, squamous cell carcinoma; CRT, chemoradiotherapy; FP, 5-fluorouracil plus cisplatin; NF,
nedaplatin plus 5-fluorouracil; RT, radiotherapy; CR, complete response
a a total pharyngolaryngoesophagectomy was performed
Table 2 Clinicopathological features of the 5 patients regarding pulmonary metastases and survival
Patient
1 2 3 4 5
DFI (months) 36 20 7 8 19
Number of metastases 1 1 2 (1)b 1 2
Diameter (mm) 9 5 20, 15 (15)c 20 6i
Treatment prior to surgery None None DOC None None
Surgical procedure Wedge resection Wedge resection Wedge resectiond Wedge resection Wedge resection
Lymph node dissection Not done Not done Not donee Not done Not done
Curability Complete resection Complete resection Complete resectionf Complete resection Complete resection
Perioperative complications None Respiratory failure Noneg None None
Postoperative hospital stay (days) 6 7 7 (6)h 4 5
OS (months) 41 29 28 90 20
Survival Alive Dead Alive Dead Alive
DFI, disease free interval; DOC, docetaxel; OS, overall survival
b,c,h The number in parentheses indicates the outcome of the second pulmonary resection
d,e,f,g The common outcome from both the first and second pulmonary resections
i Another pulmonary micrometastasis was detected by pathological examination
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Patient 3
A 68-year-old male was diagnosed with esophageal SCC
in the Ce. A pre-treatment CT-scan revealed direct inva-
sion to the trachea (clinical stage T4bN1M0). He chose
CRT as the primary treatment, and a CR was achieved.
Seven months after the start of CRT, a follow-up CT
scan revealed 2 pulmonary metastases located in the
right upper and lower lobes, and a total of 10 courses of
DOC was delivered. However, the pulmonary metastases
enlarged, resulting in PD. Subsequently, pulmonary
wedge resection was performed, and pathological com-
plete resection was achieved. Twenty-five months later, a
contralateral pulmonary metastasis developed, and pul-
monary wedge resection was performed again. The post-
operative hospital stay was 7 and 6 days after the first
and second pulmonary resections, respectively. He has
been disease free for 3 months after the second pulmon-
ary resection, and was doing well in a check-up per-
formed in the outpatient department of our institution.
Patient 4
A 68-year-old male was diagnosed with esophageal SCC
in the Ut. The clinical stage was T3N1M0 based on the
pre-treatment radiological examination. He chose CRT
as the primary treatment. In this case, nedaplatin was
administered instead of cisplatin, because the patient
had undergone a left nephrectomy due to ureteral carci-
noma. Although a CR was achieved, a follow-up CT-
scan revealed a solitary pulmonary metastasis 8 months
after the start of CRT. Pulmonary wedge resection was
performed, and pathological complete resection was
achieved. The patient’s postoperative hospital stay was 4
days. Nineteen months later, radical resection of a bone
(rib) metastasis was performed. Multiple metastases in
the local site, pleura and liver gradually developed, and
he died of disease 90 months after pulmonary resection.
Patient 5
A 55-year-old male was diagnosed with esophageal SCC
in the Ut. A pre-treatment CT scan revealed that a
metastatic lymph node had invaded to the right subcla-
vian artery (clinical stage T4bN1M0, Figure 2). CRT was
therefore administered as the primary treatment, and a
CR was achieved. Nineteen months after the start of
CRT, a follow-up CT-scan revealed a solitary pulmonary
metastasis. Pulmonary wedge resection was performed,
and the pathological examination revealed another pul-
monary micrometastasis within the resected specimen
which was not detected by the preoperative radiological
examination. Pathological complete resection of these 2
metastases was achieved. The patient’s postoperative
hospital stay was 5 days. He has been disease free for 20
months after pulmonary resection, and was doing well
in a check-up performed in the outpatient department
of our institution.
Discussion
In this article, we reviewed our institutional experience
with 5 patients who underwent surgical treatment for
pulmonary metastases from esophageal carcinoma. A
major characteristic of this article is that the primary
treatment for esophageal carcinoma was confined to
definitive CRT, and a CR was achieved in all patients.
The reported 5-year survival rate of those who are
treated with definitive CRT for esophageal cancer is
22.9% in Japan [9], and this procedure is considered to
be promising as a primary treatment, although substan-
tial toxicities are associated with the treatment [10].
While surgery still remains a standard curative treat-
ment for resectable esophageal cancer, definitive CRT
has become a prevalent alternative as a nonsurgical
treatment for unresectable esophageal carcinoma or
Figure 1 A follow-up CT scan showing a left pneumothorax,
which developed secondary to pulmonary metastasis (arrow).
Figure 2 A pre-treatment CT-scan showing metastatic lymph
node invasion to the right subclavian artery (arrow).
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potentially resectable esophageal carcinoma when
patients refuse surgery. Some retrospective studies have
reported that CRT showed comparable therapeutic
effects as esophagectomy [11,12].
In the case of local recurrence of esophageal carci-
noma after definitive CRT, salvage esophagectomy is
reported to provide a long survival for some patients,
like our current patient 1, at the cost of high rates of
morbidity and mortality [13,14]. In contrast, little is
known about the impact of surgical treatment for pul-
monary metastases from esophageal carcinoma after
definitive CRT. This is mainly because the metastases
are often detected as multiple lesions and accompanied
by metastases to other sites. Only a fraction of cases are
therefore considered to be suitable for surgical treat-
ment. As the lung is one of the most common distant
recurrence sites of esophageal carcinoma, it is necessary
to accumulate cases of the surgical treatment for pul-
monary metastases from esophageal carcinoma to eluci-
date its efficacy.
A previous report indicated that solitary pulmonary
metastasis from esophageal carcinoma was a favorable
indicator for surgical treatment [6]. In this article, 3
patients with solitary pulmonary metastasis also showed
a long survival. It is also worth noting that the other 2
patients with 2 pulmonary metastases are still alive and
disease free. Surgical treatment can therefore be benefi-
cial even for patients with more than one pulmonary
metastasis from esophageal carcinoma.
The DFI is generally recognized as a significant prog-
nostic factor after surgical treatment for pulmonary
metastases from various primary cancers [15,16]. Shiono
et al. reviewed 49 surgical cases of pulmonary metas-
tases from esophageal carcinoma. The primary treat-
ments were surgery alone (53%), radiotherapy alone
(4%), combined modality therapy (32%), and unknown
(10%). They suggested that a DFI greater than 12
months was a favorable clinical factor significantly
related to OS [7]. In this article, the DFI in patient 4
was relatively short, at 8 months, compared to the med-
ian DFI (19 months), however, that patient’s OS was 90
months, which was the longest of all of the patients.
Therefore, such patients should be kept in mind, and
the possibility of surgical treatment even in those who
develop an early recurrence should not be excluded.
The advantages of surgical resection over chemother-
apy for pulmonary metastases are a shorter hospital
stay, fewer treatment-related complications, a better PS
after treatment, and certainty of tumor removal. For
metastatic esophageal carcinoma, the standard che-
motherapeutic regimen with cisplatin and 5-fluorouracil
yields modest response rates of 25 - 33%, but a CR is
rarely achieved [17]. The benefit of chemotherapy has
yet to be proven. Moreover, chemotherapy-related
complications such as neurological, haematological, and
renal toxicities are significant, leading to a worse PS
compared to untreated patients [18]. On the other hand,
surgical treatment for pulmonary metastases is a safe
and well established procedure for properly selected
patients. All of our present patients were able to
undergo pathological complete resection by pulmonary
wedge resection, and were discharged from the hospital
within 7 days after surgery with a good PS. Even after
definitive CRT, surgical treatment for pulmonary metas-
tases from esophageal carcinoma seems to be justified.
We were able to demonstrate that the procedure has
prognostic implications, because it led to a median OS
of 29 months (range 20-90), whereas the previously
reported median OS were 24 and 27 months [6,7]. In
the previous reports, definitive CRT was not adminis-
tered as the primary treatment for esophageal carci-
noma. Although only 5 cases were included in this
study, we believe that surgical treatment for pulmonary
metastases from esophageal carcinoma can provide a
long survival for those whose primary treatment was
definitive CRT and who achieved a CR from that treat-
ment. Taken together, our findings indicate that surgical
treatment can presumably be used an alternative to sys-
temic chemotherapy in treating pulmonary metastases
from esophageal carcinoma, if the patients meet the
above described criteria.
Conclusions
Surgical treatment should be taken into consideration
for patients with pulmonary metastases from esophageal
carcinoma who previously received CRT and achieved a
therapeutic CR, because it can provide not only a longer
survival, but also a good postoperative PS for some
patients.
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